Literature DB >> 18234554

Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.

Andrew T Yan1, Raymond T Yan, Francis G Spinale, Rizwan Afzal, Himali R Gunasinghe, Robert E Stroud, Robert S McKelvie, Peter P Liu.   

Abstract

BACKGROUND: Both neurohormonal derangements and alterations in the myocardial extracellular matrix are thought to contribute to adverse ventricular remodelling that results in worsening heart failure (HF). There is also emerging preclinical information to suggest that these signalling pathways mutually regulate in HF. AIM: To assess the relationships between plasma levels of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinase (TIMP), and neurohormonal profiles in chronic HF. METHODS AND
RESULTS: In this substudy of 184 HF patients enrolled in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) trial, plasma norepinephrine and epinephrine were measured with HPLC; atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), angiotensin II, aldosterone, and endothelin-1 were measured with immunoassays; MMP-2, MMP-9, and TIMP-1 were measured with 2-site sandwich ELISA assays. We used Spearman's rank correlation to examine the relationships between plasma MMP and neurohormone levels. Circulating ANP, BNP, and endothelin-1 levels were positively correlated with MMP-2 and TIMP-1 levels. Plasma level of aldosterone showed a weak positive correlation with MMP-9, but there was no significant correlation between angiotensin II, epinephrine or norepinephrine and MMP-2, MMP-9, or TIMP-1.
CONCLUSIONS: These findings suggest that specific neurohormones and extracellular matrix modulators may play a coordinated role in the pathogenesis of HF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234554      PMCID: PMC2693229          DOI: 10.1016/j.ejheart.2007.12.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  23 in total

1.  Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.

Authors:  George Suzuki; Hideaki Morita; Takayuki Mishima; Victor G Sharov; Anastassia Todor; Elaine J Tanhehco; Amy E Rudolph; Ellen G McMahon; Sidney Goldstein; Hani N Sabbah
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.

Authors: 
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

3.  Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure.

Authors:  Cristina Banfi; Viviana Cavalca; Fabrizio Veglia; Maura Brioschi; Simona Barcella; Luciana Mussoni; Loredana Boccotti; Elena Tremoli; Paolo Biglioli; Piergiuseppe Agostoni
Journal:  Eur Heart J       Date:  2004-12-17       Impact factor: 29.983

4.  Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.

Authors:  Toshihiro Tsuruda; Guido Boerrigter; Brenda K Huntley; Josh A Noser; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Horng H Chen; John C Burnett
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

Review 5.  Matrix metalloproteinases: regulation and dysregulation in the failing heart.

Authors:  Francis G Spinale
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

6.  Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation.

Authors:  M L Coker; J R Jolly; C Joffs; T Etoh; J R Holder; B R Bond; F G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-08       Impact factor: 4.733

Review 7.  Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation.

Authors:  Anne M Deschamps; Francis G Spinale
Journal:  Cardiovasc Res       Date:  2006-01-19       Impact factor: 10.787

8.  Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.

Authors:  Andrew T Yan; Raymond T Yan; Francis G Spinale; Rizwan Afzal; Himali R Gunasinghe; Malcolm Arnold; Catherine Demers; Robert S McKelvie; Peter P Liu
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

9.  N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.

Authors:  Dimitrios N Tziakas; Georgios K Chalikias; Eleni I Hatzinikolaou; Dimitrios A Stakos; Ioannis K Tentes; Alexandros Kortsaris; Dimitrios I Hatseras; Juan Carlos Kaski
Journal:  Am J Cardiol       Date:  2005-07-01       Impact factor: 2.778

10.  Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.

Authors:  J T Peterson; H Hallak; L Johnson; H Li; P M O'Brien; D R Sliskovic; T M Bocan; M L Coker; T Etoh; F G Spinale
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

View more
  8 in total

1.  Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling.

Authors:  Stephanie L Thorn; Shayne C Barlow; Attila Feher; Mitchel R Stacy; Heather Doviak; Julia Jacobs; Kia Zellars; Jennifer M Renaud; Ran Klein; Robert A deKemp; Aarif Y Khakoo; TaeWeon Lee; Francis G Spinale; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2019-11-11       Impact factor: 7.792

2.  Micropatterned sensing hydrogels integrated with reconfigurable microfluidics for detecting protease release from cells.

Authors:  Kyung Jin Son; Dong-Sik Shin; Timothy Kwa; Yandong Gao; Alexander Revzin
Journal:  Anal Chem       Date:  2013-11-26       Impact factor: 6.986

3.  Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.

Authors:  Brendan P Purcell; Shayne C Barlow; Paige E Perreault; Lisa Freeburg; Heather Doviak; Julia Jacobs; Abigail Hoenes; Kia N Zellars; Aarif Y Khakoo; TaeWeon Lee; Jason A Burdick; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-06       Impact factor: 4.733

4.  Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha.

Authors:  David B Murray; Scott P Levick; Gregory L Brower; Joseph S Janicki
Journal:  J Mol Cell Cardiol       Date:  2010-04-18       Impact factor: 5.000

5.  Micropatterned surfaces functionalized with electroactive peptides for detecting protease release from cells.

Authors:  Dong-Sik Shin; Ying Liu; Yandong Gao; Timothy Kwa; Zimple Matharu; Alexander Revzin
Journal:  Anal Chem       Date:  2012-12-14       Impact factor: 6.986

Review 6.  The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.

Authors:  Daniela-Eugenia Malliga; Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2011-09-02

7.  Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?

Authors:  Patrick Badertscher; David Gregg; Catalin F Baicu; Viswanathan Ramakrishnan; Francis G Spinale; Michael R Zile; Michael R Gold
Journal:  Heart Rhythm O2       Date:  2021-01-12

8.  Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery.

Authors:  Suzana Bojic; Jelena Kotur-Stevuljevic; Aleksandra Aleksic; Jasna Gacic; Lidija Memon; Sanja Simic-Ogrizovic
Journal:  Dis Markers       Date:  2018-05-16       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.